Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9645837 | 0.93 | ALDH1A1 (0.54) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL7407539 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL5362357 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL9863328 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL7094911 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL4090218 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL7411952 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL19664310 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL7359556 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53TSHRCHRM5CHRM1 | |
| SCHEMBL1830509 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461055-B | Prodrugs of neuroactive steroids | 腾盛博药生物科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20230416298-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | BRII BIOSCIENCES, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4110345-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | Brii Biosciences, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115461055-A | Prodrugs of neuroactive steroids | 腾盛博药生物科技有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-7803785-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2010036910-A1 | HEART PROTECTION BY ADMINISTERING AN AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | OHTA YOSHIKAZU (JP) | 2010-04-01 | — | — | WO | disclosed |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7608602-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| CN-100430390-C | Water-soluble triazole antifungal agents | SANKYO CO (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1362856-B1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | DAIICHI SANKYO CO LTD (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7230023-B2 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2007-06-12 | — | — | US | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| CN-1720913-A | Water-soluble triazole fungicide | SANKYO CO (JP) | 2006-01-18 | — | — | CN | disclosed |
| EP-1567169-A2 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040198790-A1 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| US-20040142857-A1 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. | 2004-07-22 | — | — | US | disclosed |
| CN-1503795-A | Water-soluble triazole antifungal agents | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| WO-2004041203-A2 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-1362856-A1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
| CN-1264371-A | Pyrazine derivatives, their preparation and medicines containing them | RHONE POULENC RORER SA (FR) | 2000-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142857-A1 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | TYMP, GDA, GCG | ALDH1A1 1596/4885TP53 68/4885TSHR 4399/4885 |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TYMP, GDA, GCG | ALDH1A1 1615/4885TP53 90/4885TSHR 4354/4885 |
| US-20230416298-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | NR3C1, PGR, GABRD | ALDH1A1 1077/4885TP53 4708/4885TSHR 814/4885 |
| US-20040198790-A1 | Water-soluble triazole fungicide | ERG28, CYP51A1, XDH | ALDH1A1 1619/4885TP53 1148/4885TSHR 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.